Natural Splendid Enterprises Ltd. (OTCMKTS:NSPDF) announced that it has shipped a second container of hemp seed to South Korea.
Natural Splendid ships hemp seed to South Korea
The company finalized the processing of a shipping order from South Korea for a 40-foot container of hem seed. This will be a second shipment of almost 20 tonnes the Vancouver-based company is making to South Korea since March 2020 There has been increased demand for its healthy and safe food from Southeast Asia. Natural Splendid informed shareholders that this latest hemp order will be a platform for discussing business opportunities to export more hemp seeds to the region.
Craig Godwin, the company’s CEO, indicated that the company’s first hemp seed containers were shipped to the region in 2016. He added that following this latest order, they are delighted with an increase in interest for hemp in the region.
Natural Splendid provides CTA update for COVID-19 treatment
Goodwin also offered update regarding the company’s clinical study joint venture with Biologic Pharmaceutical Research. The study employs one of the patented technologies of Biologic as a potential candidate for COVID-19 treatment. The potential treatment, which will be in the form of a capsule has the potential to eliminate or significantly reduce the need for COVID-19 patients to visit health facilities for infusions or other therapies.
Recently the company submitted a Clinical Trial Application (CTA) to Health Canada for potential COVID-19 therapy. The regulator approved the application on May 17, 2020, and subsequently moved the submission down to the review process. Health Canada requested further information regarding the application, which the company submitted on June 1 and 2, 2020.
The company is encouraged by Health Canada’s support and communication, expecting direction from the company. The potential COVID-19 treatment, Cavaltinib(R), will help individuals at risk of mortality and morbidity. Cavaltinib has demonstrated the potential of inhibiting transcription factors that are vital in cytokine production. The exclusive license for Cavaltinib will be held through a joint venture between the company and Biologic Pharmaceutical.
Emerald Health Therapeutics Inc. (OTCMKTS:EMHTF) Introduces Pure Sunfarm Products In Manitoba As Its Terminates Facility Agreements
Post Views: 96 Emerald Health Therapeutics Inc. (OTCMKTS:EMHTF) has announced that its cannabis production joint venture Pure Sunfarms has started...
Planet 13 Holdings Inc. (OTCMKTS:PLNHF) Signs Purchase Agreement To Acquire 45,000 Sq. ft. Facility In Nevada
Post Views: 189 Planet 13 Holdings Inc. (OTCMKTS:PLNHF) announced the signing of an asset purchase agreement subject to which it...
AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) Unveils its NeuCovix™ Test That Can Accurately Classify COVID-19 Neutralization Tests
Post Views: 61 AXIM® Biotechnologies Inc. (OTCMKTS:AXIM) has completed a study focusing on the performance of its NeuCovix™ rapid test...
Indus Holdings Inc. (OTCMKTS:INDXF) Terminates Its Pending $20 million Acquisition Agreement Of W Vapes Assets
Post Views: 185 Indus Holdings Inc. (OTCMKTS:INDXF) announced termination of its impending acquisition of W Vapes assets that was announced...
1933 Industries Inc. (OTCMKTS:TGIFF) Introduces Pre-roll Joints And Smokable Cannabis Flower In Nevada
Post Views: 165 1933 Industries Inc. (OTCMKTS:TGIFF) announced addition of pre-joint rolls and high-quality smokable flowers to its growing consumer...
Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) Initiates Expansion Of Its Cannabinoid Diagnostic Platform Tests In Europe
Post Views: 134 Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) commenced expansion in the European markets to offer cancer patients tailored cannabinoid treatment...